Kim Jackson, MD
Allergy & Immunology · Little Rock, ARNPI 1902292329
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 342 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,976, 6.1 times the $325 reported in 2019.
Across 342 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Sanofi$899
- AstraZeneca$648
- Regeneron Healthcare Solutions, Inc.$575
- Genentech USA, Inc.$450
- Novartis$428
- plus $2K from 23 others
What the payments were for
- Consulting fees$541%
- Food & beverage$6,31798%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 80 | $1,080 |
| Sanofi | 38 | $899 |
| AstraZeneca | 33 | $648 |
| Regeneron Healthcare Solutions, Inc. | 22 | $575 |
| Genentech USA, Inc. | 25 | $450 |
| Novartis | 25 | $428 |
| CSL Behring | 19 | $359 |
| Pharming Healthcare, Inc. | 14 | $326 |
| Amgen | 14 | $261 |
| Biocryst US Sales Co., LLC | 8 | $183 |
| LEO Pharma Inc. | 10 | $177 |
| Grifols USA, LLC | 7 | $148 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $129 |
| Sanofi-aventis U.S. LLC | 6 | $111 |
| Pfizer | 5 | $110 |
| Kaleo, Inc. | 5 | $104 |
| Hikma Pharmaceuticals USA | 5 | $92 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $69 |
| ADMA Biomanufacturing LLC | 3 | $54 |
| Mylan Specialty L.p. | 2 | $48 |
| Paratek Pharmaceuticals, Inc. | 2 | $39 |
| Boehringer Ingelheim | 2 | $33 |
| Greer Laboratories, Inc. | 1 | $24 |
| Verona Pharma, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Optinose US, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$6,451 in reported general payments places this provider in the 65th percentile of 26 allergy & immunology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 22 | $94,085 |
| SymbicortBudesonide/Formoterol Fumarate | 57 | $14,633 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $13,113 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,030 |
| Arnuity ElliptaFluticasone Furoate | 44 | $12,043 |
| Epinephrine | 46 | $8,493 |
| Qvar RedihalerBeclomethasone Dipropionate | 17 | $7,967 |
| Azelastine Hcl | 276 | $7,380 |
| Spiriva HandihalerTiotropium Bromide | 12 | $6,246 |
| Fluticasone Propionate | 298 | $3,202 |
| BreynaBudesonide/Formoterol Fumarate | 16 | $2,402 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 69 | $1,741 |
| Tacrolimus | 13 | $1,682 |
| Ipratropium Bromide | 47 | $1,556 |
| Montelukast Sodium | 204 | $1,378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $1,080 | $38,18697 claims |
| AstraZenecaSymbicort | $648 | $14,63357 claims |
| Hikma Pharmaceuticals USAEpinephrine | $92 | $8,49346 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $12 | $7,96717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 26 allergy & immunology providers in Arkansas.
Other allergy & immunology in Little Rock
- Blake ScheerLittle Rock$81K
- Jim IngramLittle Rock$62K
- Karl SitzLittle Rock$19K
- Stacy GriffinLittle Rock$10K
- Ashley StonerLittle Rock$7K
- Adam PriceLittle Rock$4K
- Lori KagyLittle Rock$4K
- Gene FranceLittle Rock$2K
- Joshua KennedyLittle Rock$2K
- Meredith DilleyLittle Rock$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.